ARS Pharma posts Q3 2026 results, highlights neffy share gains and CSU trial timeline
The company reported $37.7 million in third-quarter revenue and said interim Phase 2b data for its chronic urticaria candidate ARS-2 are due in early 2027.
SEC filing